19-05-2025
Petra Capital Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)
In a report released on May 16, Tanushree Jain from Petra Capital maintained a Buy rating on Neuren Pharmaceuticals Limited (NURPF – Research Report), with a price target of A$31.45. The company's shares closed last Monday at $8.14.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Jain is ranked #778 out of 9519 analysts.
Currently, the analyst consensus on Neuren Pharmaceuticals Limited is a Strong Buy with an average price target of $17.11, an 110.25% upside from current levels. In a report released on May 9, Bell Potter also maintained a Buy rating on the stock with a A$20.00 price target.
NURPF market cap is currently $1.08B and has a P/E ratio of 11.50.
